Company: ZVRA
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001434647-25-000011
Chunk: 134

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 134
---
 of common stock for future issuance as follows:September 30,2025December 31,2024Outstanding awards under equity incentive plans7,228,5557,789,658Outstanding common stock warrants4,436,6375,483,537Possible future issuances under equity incentive plans6,422,6375,383,165Possible future issuances under employee stock purchase plans1,055,6851,148,012Total common shares reserved for future issuance19,143,51419,804,372Common Stock ActivityThe following table summarizes common stock activity for the three and nine months ended September 30, 2025:Shares of Common StockBalance as of January 1, 202553,670,709Common stock issued as compensation to third parties9,306Common stock issued as a result of stock options exercised or RSUs vested999,338Common stock issued as a result of stock warrants exercised10Balance as of March 31, 202554,679,363Common stock issued as a result of stock options exercised or RSUs vested312,514Common stock issued as a result of the Employee Stock Purchase Plan92,327Balance as of June 30, 202555,084,204Common stock issued as a result of stock options exercised or RSUs vested86,628Common stock issued as a result of stock warrants exercised1,046,890Balance as of September 30, 202556,217,722

20

Authorized, Issued, and Outstanding Preferred StockAs of September 30, 2025, and December 31, 2024, the Company had 10,000,000 shares of authorized preferred stock, none of which were designated, issued, or outstanding.Warrants to Purchase Common StockThe Company has issued warrants to purchase common stock to various third parties, of which 4,436,637 remain outstanding as of September 30, 2025, and are immediately exercisable. These warrants qualify as participating securities under ASC Topic 260, Earnings per Share, and are treated as such in the net income (loss) per share calculation. The Company may be required to redeem these warrants for a cash amount equal to the BSM value of the portion of the warrants to be redeemed.While the warrants are outstanding (but unexercised), the warrant holders will participate in any dividend or other distribution of the Company’s assets to its common stockholders by way of return of capital or otherwise. As of September 30, 2025, 1